Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247299355> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- W2247299355 abstract "14152 Background: Survival for patients with unresectable cholangiocarcinoma is reported to be 5–8 months. Systemic chemotherapy has been disappointing and not shown to significantly improve survival. Transcatheter arterial chemoembolization (TACE) has been shown to prolong survival in hepatocellular carcinoma patients but experience with cholangiocarcinoma is limited. We report our experience with the well-tolerated drug gemcitabine. Methods: Thirty-eight patients with unresectable cholangiocarcinoma were treated with one or more cycles of gemcitabine-based TACE between 2001 and 2005 at our institution. Follow-up imaging was performed on all patients after each TACE procedure. Regimens of TACE included: gemcitabine only (16), gemcitabine followed by cisplatin (2), gemcitabine followed by oxaliplatin (5), gemcitabine and cisplatin (12), and gemcitabine and cisplatin followed by oxaliplatin (3). Actual survival is reported, as 35 of 38 have died from disease (92%). Results: Patients were 57.5 years of age (range 36–87) and a median of 3 treatments (range 1–10) were administered. Median survival from time of first treatment was 10.3 months. Patients receiving gemcitabine followed by cisplatin or oxaliplatin had improved survival (mean 16.5 and 10.5 months respectively) when compared to gemcitabine alone (mean 6 months). Patients receiving gemcitabine and cisplatin as a combination had improved survival (mean 13.4 months) compared to single agent gemcitabine. Patients who progressed on gemcitabine and cisplatin and then received oxaliplatin also showed improved survival (mean 14.3 months) compared to gemcitabine only. Neutropenia, thrombocytopenia and hyperbilirubinemia were the most common toxicities observed. Three patients in the entire series exhibited grade 3 thrombocytopenia while seven patients had grade 3 and one had grade 4 bilirubin levels. Conclusions: This series provides evidence in favor of TACE rather than historically reported alternatives such as systemic chemotherapy or chemotherapy/RT. Our results suggest that gemcitabine based TACE is well tolerated and perhaps best delivered as a combination therapy for patients with unresectable cholangiocarcinoma. No significant financial relationships to disclose." @default.
- W2247299355 created "2016-06-24" @default.
- W2247299355 creator A5003320997 @default.
- W2247299355 creator A5007740121 @default.
- W2247299355 creator A5051148693 @default.
- W2247299355 creator A5067576970 @default.
- W2247299355 date "2006-06-20" @default.
- W2247299355 modified "2023-09-24" @default.
- W2247299355 title "Gemcitabine-based transcatheter arterial chemoembolization for unresectable cholangiocarcinoma in thirty-eight patients: Single institutional experience" @default.
- W2247299355 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.14152" @default.
- W2247299355 hasPublicationYear "2006" @default.
- W2247299355 type Work @default.
- W2247299355 sameAs 2247299355 @default.
- W2247299355 citedByCount "0" @default.
- W2247299355 crossrefType "journal-article" @default.
- W2247299355 hasAuthorship W2247299355A5003320997 @default.
- W2247299355 hasAuthorship W2247299355A5007740121 @default.
- W2247299355 hasAuthorship W2247299355A5051148693 @default.
- W2247299355 hasAuthorship W2247299355A5067576970 @default.
- W2247299355 hasConcept C126322002 @default.
- W2247299355 hasConcept C126838900 @default.
- W2247299355 hasConcept C143998085 @default.
- W2247299355 hasConcept C2776694085 @default.
- W2247299355 hasConcept C2778019345 @default.
- W2247299355 hasConcept C2778455285 @default.
- W2247299355 hasConcept C2780258809 @default.
- W2247299355 hasConcept C71924100 @default.
- W2247299355 hasConcept C90924648 @default.
- W2247299355 hasConceptScore W2247299355C126322002 @default.
- W2247299355 hasConceptScore W2247299355C126838900 @default.
- W2247299355 hasConceptScore W2247299355C143998085 @default.
- W2247299355 hasConceptScore W2247299355C2776694085 @default.
- W2247299355 hasConceptScore W2247299355C2778019345 @default.
- W2247299355 hasConceptScore W2247299355C2778455285 @default.
- W2247299355 hasConceptScore W2247299355C2780258809 @default.
- W2247299355 hasConceptScore W2247299355C71924100 @default.
- W2247299355 hasConceptScore W2247299355C90924648 @default.
- W2247299355 hasLocation W22472993551 @default.
- W2247299355 hasOpenAccess W2247299355 @default.
- W2247299355 hasPrimaryLocation W22472993551 @default.
- W2247299355 hasRelatedWork W1972888300 @default.
- W2247299355 hasRelatedWork W2056126657 @default.
- W2247299355 hasRelatedWork W2100029565 @default.
- W2247299355 hasRelatedWork W2349270370 @default.
- W2247299355 hasRelatedWork W2353066579 @default.
- W2247299355 hasRelatedWork W2381460883 @default.
- W2247299355 hasRelatedWork W2591479921 @default.
- W2247299355 hasRelatedWork W2746579122 @default.
- W2247299355 hasRelatedWork W3032035276 @default.
- W2247299355 hasRelatedWork W3210122607 @default.
- W2247299355 isParatext "false" @default.
- W2247299355 isRetracted "false" @default.
- W2247299355 magId "2247299355" @default.
- W2247299355 workType "article" @default.